Brendan Manning, Ph.D.

Brendan Manning, Ph.D.

Professor and Acting Chair, Department of Molecular Metabolism (Harvard T.H. Chan School of Public Health
Affiliate Member of Cell Biology (HMS)

Brendan Manning, Ph.D. is a Professor and Acting Chair in the Department of Molecular Metabolism at the Harvard T.H. Chan School of Public Health. He received his PhD from Yale University in 2000 and was a postdoctoral fellow at Harvard Medical School. In 2004, Dr. Manning became the first faculty member hired in the then newly established Department of Genetics and Complex Diseases (later changed to Molecular Metabolism) at Harvard-Chan. Dr. Manning was an inaugural recipient of the National Cancer Institute’s Outstanding Investigator Award. 

Research in the Manning lab is defining the molecular interface between cellular signaling networks and metabolic networks, as it relates to both normal physiology and diseases with metabolic dysregulation as a key feature, including cancer, diabetes, and aging-related diseases. Research efforts are focused in part on defining the regulatory mechanisms and functions of a signaling network converging on the tuberous sclerosis complex (TSC) protein complex and the mammalian target of rapamycin (mTOR), which relay an array of extracellular and intracellular growth signals to control the balance between anabolic and catabolic metabolism in cells, tissues, and tumors.

665 Huntington Ave

SPH2-117

Boston, MA 02115

Management of spontaneous rupture of the oesophagus (Boerhaave's syndrome): single centre experience of 18 cases.
Authors: Authors: Prichard R, Butt J, Al-Sariff N, Frohlich S, Murphy S, Manning B, Ravi N, Reynolds JV.
Ir J Med Sci
View full abstract on Pubmed
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Authors: Authors: Kwiatkowski DJ, Manning BD.
Hum Mol Genet
View full abstract on Pubmed
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2.
Authors: Authors: Manning BD, Logsdon MN, Lipovsky AI, Abbott D, Kwiatkowski DJ, Cantley LC.
Genes Dev
View full abstract on Pubmed
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
Authors: Authors: Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG.
Genes Dev
View full abstract on Pubmed
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.
Authors: Authors: Manning BD.
J Cell Biol
View full abstract on Pubmed
The LKB1 tumor suppressor negatively regulates mTOR signaling.
Authors: Authors: Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, Cantley LC.
Cancer Cell
View full abstract on Pubmed
Rheb fills a GAP between TSC and TOR.
Authors: Authors: Manning BD, Cantley LC.
Trends Biochem Sci
View full abstract on Pubmed
Targeting the PI3K-Akt pathway in human cancer: rationale and promise.
Authors: Authors: Luo J, Manning BD, Cantley LC.
Cancer Cell
View full abstract on Pubmed
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Authors: Authors: Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J.
Curr Biol
View full abstract on Pubmed
United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling.
Authors: Authors: Manning BD, Cantley LC.
Biochem Soc Trans
View full abstract on Pubmed